NeuroSense Therapeutics (NASDAQ:NRSNW – Get Free Report) is expected to be releasing its results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($0.1950) per share and revenue of $0.2680 million for the quarter.
NeuroSense Therapeutics Stock Performance
Shares of NASDAQ:NRSNW opened at $0.07 on Monday. The business has a fifty day moving average of $0.10 and a two-hundred day moving average of $0.14. NeuroSense Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.70.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Further Reading
- Five stocks we like better than NeuroSense Therapeutics
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
